United Kingdom - English - MHRA (Medicines & Healthcare Products Regulatory Agency)

wockhardt uk ltd - flucloxacillin sodium - powder for solution for injection - 500mg

Australia - English - Department of Health (Therapeutic Goods Administration)

apotex pty ltd - flucloxacillin sodium monohydrate -

Australia - English - Department of Health (Therapeutic Goods Administration)

apotex pty ltd - flucloxacillin sodium monohydrate -

United States - English - NLM (National Library of Medicine)

a-s medication solutions - dicloxacillin sodium (unii: 4hzt2v9kx0) (dicloxacillin - unii:cof19h7wbk) - dicloxacillin 250 mg - to reduce the development of drug-resistant bacteria and maintain the effectiveness of dicloxacillin sodium capsules and other antibacterial drugs, dicloxacillin sodium capsules should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. when culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. in the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. dicloxacillin is indicated in the treatment of infections caused by penicillinase-producing staphylococci which have demonstrated susceptibility to the drug. cultures and susceptibility tests should be performed initially to determine the causative organisms and their sensitivity to the drug (see clinical pharmacology – susceptibility  testing ). dicloxacillin may be used to initiate therapy in suspected cases of resistant staphylococcal infections prior to the availability of laboratory test results. the penicillinase-resistant penicillins should not be used in infections caused by organisms susceptible to penicillin g. if the susceptibility tests indicate that the infection is due to an organism other than a resistant staphylococcus, therapy should not be continued with a penicillinase-resistant penicillin. dicloxacillin sodium is contraindicated in persons who have shown hypersensitivity to any of the penicillins or any component of the formulations.

New Zealand - English - Medsafe (Medicines Safety Authority)

viatris limited - flucloxacillin sodium monohydrate 545mg (quantity variable: based on the assay of flucloxacillin sodium) - capsule - 500 mg - active: flucloxacillin sodium monohydrate 545mg (quantity variable: based on the assay of flucloxacillin sodium) excipient: capsugel black 01.911 capsugel yellow 42.957 magnesium stearate microcrystalline cellulose povidone purified talc sodium starch glycolate - the treatment of infections due to sensitive gram-positive organisms, including beta-lactamase producing staphylococci and streptococci.

Australia - English - APVMA (Australian Pesticides and Veterinary Medicines Authority)

norbrook laboratories australia pty limited - ampicillin as the sodium salt; cloxacillin as sodium monohydrate salt - misc. intra mammary - ampicillin as the sodium salt antibiotic active 75.0 mg/5gsyr; cloxacillin as sodium monohydrate salt antibiotic active 200.0 mg/5gsyr - antibiotic & related - dairy cattle lactating | bovine | milking cow - antibiotic - anti-infective | antibiotics - oral, parenteral | arcanobacterium spp. | bacterial infection | corynebacterium spp. | escherichia coli (e. coli) | mastitis | organisms sensitive to cloxacillin | staphylococcus spp. | streptococcus agalactiae | streptococcus spp. | abrasions | abscesses | airsacculitis | amoxycillin sensitive bacteria | anaerobic bacterial infection | antiseptic | associated with viral disease | avian mycoplasmas | bacterial canker | blackhead | body odours | bowed tendons | broad spectrum | burns | clavulanic acid sensitive | coccidiosis | coliform complex | conjunctivitis | coryza | cowpox | cracks | crd | crusts | dandruff | dermatological disorders | dermatoses | dermatosis | diarrhoea | dry skin | dysentery | eczema | endometritis | enteric diseases | enteritis | enzootic pneumonia | escherichia coli | european brood disease | feed efficiency | fungal infections | gentamicin sensitive | girth galls | gram negative organisms | gram positive organisms | hypermotility | includin

New Zealand - English - Medsafe (Medicines Safety Authority)

glaxosmithkline nz limited - flucloxacillin sodium monohydrate 544mg equivalent to 500 mg flucloxacillin free acid;  ;   - powder for injection - 500 mg - active: flucloxacillin sodium monohydrate 544mg equivalent to 500 mg flucloxacillin free acid    

Australia - English - Department of Health (Therapeutic Goods Administration)

apotex pty ltd - flucloxacillin sodium monohydrate -

Australia - English - Department of Health (Therapeutic Goods Administration)

apotex pty ltd - flucloxacillin sodium monohydrate -

United States - English - NLM (National Library of Medicine)

redpharm drug, inc. - dicloxacillin sodium (unii: 4hzt2v9kx0) (dicloxacillin - unii:cof19h7wbk) - the penicillinase-resistant penicillins are indicated in the treatment of infections caused by penicillinase-producing staphylococci which have demonstrated susceptibility to the drugs. cultures and susceptibility tests should be performed initially to determine the causative organism and their sensitivity to the drug (see clinical pharmacology – susceptibility testing). the penicillinase-resistant penicillins may be used to initiate therapy in suspected cases of resistant staphylococcal infections prior to the availability of laboratory test results. the penicillinase-resistant penicillins should not be used in infections caused by organisms susceptible to penicillin g. if the susceptibility tests indicate that the infection is due to an organism other than a resistant staphylococcus, therapy should not be continued with a penicillinase-resistant penicillin. to reduce the development of drug-resistant bacteria and maintain the effectiveness of dicloxacillin sodium capsules and other antibacterial drugs, dicl